Literature DB >> 24927705

Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions.

Geidy E Serrano1, Marwan N Sabbagh1, Lucia I Sue1, Jose A Hidalgo1, Julie A Schneider2, Barry J Bedell3, Vivianna M Van Deerlin4, Eunran Suh4, Haruhiko Akiyama5, Abhinay D Joshi6, Michael J Pontecorvo6, Mark A Mintun6, Thomas G Beach1.   

Abstract

Abnormal neuronal accumulation and modification of TAR DNA binding protein 43 (TDP-43) have recently been discovered to be defining histopathological features of particular subtypes of frontotemporal dementia and amyotrophic lateral sclerosis, and are also common in aging, particularly coexisting with hippocampal sclerosis and Alzheimer's disease pathology. This case report describes a 72 year old Hispanic male with no family history of neurological disease, who presented at age 59 with obsessive behavior, anxiety, agitation, and dysphasia. Positron emission tomography imaging using the amyloid ligand 18F florbetapir (Amyvid) was positive. Postmortem examination revealed frequent diffuse and neuritic amyloid plaques throughout the cerebral cortex, thalamus, and striatum, Braak stage II neurofibrillary degeneration, and frequent frontal and temporal cortex TDP-43-positive neurites with rare nuclear inclusions. The case is unusual and instructive because of the co-existence of frequent cortical and diencephalic amyloid plaques with extensive TDP-43-positive histopathology in the setting of early-onset dementia and because it demonstrates that a positive cortical amyloid imaging signal in a subject with dementia does not necessarily establish that Alzheimer's disease is the sole cause.

Entities:  

Keywords:  Alzheimer's disease; frontotemporal dementia; neuritic amyloid plaques; neurofibrillary degeneration

Mesh:

Substances:

Year:  2014        PMID: 24927705      PMCID: PMC4167919          DOI: 10.3233/JAD-140162

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  26 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

2.  Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors:  Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

3.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

4.  Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections.

Authors:  H Braak; E Braak
Journal:  Brain Pathol       Date:  1991-04       Impact factor: 6.508

5.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.

Authors:  Johannes Brettschneider; Vivianna M Van Deerlin; John L Robinson; Linda Kwong; Edward B Lee; Yousuf O Ali; Nathaniel Safren; Mervyn J Monteiro; Jon B Toledo; Lauren Elman; Leo McCluskey; David J Irwin; Murray Grossman; Laura Molina-Porcel; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-03-18       Impact factor: 17.088

Review 6.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

7.  Clinicopathologic differences among patients with behavioral variant frontotemporal dementia.

Authors:  Mario F Mendez; Aditi Joshi; Kanida Tassniyom; Edmond Teng; Jill S Shapira
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

8.  Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.

Authors:  K A Josephs; J L Whitwell; D S Knopman; W T Hu; D A Stroh; M Baker; R Rademakers; B F Boeve; J E Parisi; G E Smith; R J Ivnik; R C Petersen; C R Jack; D W Dickson
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

9.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

Review 10.  The many ways to frontotemporal degeneration and beyond.

Authors:  O Bugiani
Journal:  Neurol Sci       Date:  2007-10       Impact factor: 3.307

View more
  10 in total

Review 1.  Future Directions in Imaging Neurodegeneration.

Authors:  Joseph C Masdeu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

2.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh
Journal:  Neuropathology       Date:  2015-01-26       Impact factor: 1.906

Review 3.  Imaging frontotemporal lobar degeneration.

Authors:  Janine Diehl-Schmid; Oezguer A Onur; Jens Kuhn; Traugott Gruppe; Alexander Drzezga
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

Review 4.  Neuroimaging in Frontotemporal Lobar Degeneration: Research and Clinical Utility.

Authors:  Sheena I Dev; Bradford C Dickerson; Alexandra Touroutoglou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old.

Authors:  Thomas G Beach; Michael Malek-Ahmadi
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 6.  A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?

Authors:  Thomas G Beach
Journal:  Neurol Ther       Date:  2017-07-21

7.  Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementia.

Authors:  Elisa Canu; Federica Agosta; Gorana Mandic-Stojmenovic; Tanja Stojković; Elka Stefanova; Alberto Inuggi; Francesca Imperiale; Massimiliano Copetti; Vladimir S Kostic; Massimo Filippi
Journal:  Neuroimage Clin       Date:  2017-05-25       Impact factor: 4.881

8.  Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia.

Authors:  Thomas G Beach; Charles H Adler; Nan Zhang; Geidy E Serrano; Lucia I Sue; Erika Driver-Dunckley; Shayamal H Mehta; Edouard E Zamrini; Marwan N Sabbagh; Holly A Shill; Christine M Belden; David R Shprecher; Richard J Caselli; Eric M Reiman; Kathryn J Davis; Kathy E Long; Lisa R Nicholson; Anthony J Intorcia; Michael J Glass; Jessica E Walker; Michael M Callan; Javon C Oliver; Richard Arce; Richard C Gerkin
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

Review 9.  Neuroimaging in aging and neurologic diseases.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Handb Clin Neurol       Date:  2019

Review 10.  Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.

Authors:  Magdalena Korecka; Leslie M Shaw
Journal:  J Neurochem       Date:  2021-08-25       Impact factor: 5.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.